Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2736 Second Primary Neoplasms in Patients with Neuroendocrine Neoplasms (NEN): DATA from a Retrospective Multicentric Study

Introduction: Patients with sporadic gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) may exhibit a higher risk of second primary tumors than the general population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Massironi S

Authors: Massironi S, Campana D, Pusceddu S, Albertelli M, Faggiano A,

Keywords: GEP-NEN, Second primary neoplasm (PMN), Overall survival (OS),

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,

#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Chan D, Ferone D, Segelov E, Albertelli M, Singh S,

Keywords: Escalated dose, octreotide, lanreotide, SSA,

#1538 Safety of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: Dose escalation (or interval reduction) of somatostatin analogs (SSAs) is a rather common strategy for patients (pts) with progressive metastatic neuroendocrine tumors (NETs). However, to date, no systematic prospective studies have been carried out to evaluate safety and efficacy of this treatment schedule in NETs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: high doses lanreotide safety ,

#837 Does Biopsy Reliably Identify Grade In Gastroenteropancreatic Neuroendocrine Tumors?

Introduction: A new proliferation-based grading system has proved important in establishing prognosis and guiding therapy in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Biopsies are often performed for grading but little is known about their reliability in assigning grade.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Grillo F

Authors: Grillo F, Brisigotti M, Albertelli M, Mastracci L, Fiocca R,

Keywords: neuroendocrine, grade, biopsy,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.